Qiagen, QGEN

Qiagen stock at USD 45.47 on September 28, 2026

Published on 09/28/2026 at 19:18 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Qiagen stock last traded at USD 45.47 on September 28, 2026, up 2.92 percent. QIAGEN announced FDA clearance for a new QIAstat-Dx bloodstream infection panel.

Pipette tropft klare Flüssigkeit in sterile 96-Well-Platte, klinisches Laborlicht
Qiagen N.V. (NL0012169213) Pipette tropft klare Flüssigkeit in sterile 96-Well-Platte im klinischen Labor, Illustration mit AI erstellt.

Trading session

Qiagen N.V. shares traded on the New York Stock Exchange under the ticker QGEN at USD 45.47 at 17:17:36 UTC on September 28, 2026. The stock was up USD 1.29, or 2.92 percent, from the previous close of USD 44.18. The exchange session was still open at the recorded time.

FDA clearance expands QIAstat-Dx portfolio

On September 28, 2026, QIAGEN N.V. said the U.S. Food and Drug Administration had cleared a new QIAstat-Dx bloodstream infection panel. The company said the clearance gives U.S. laboratories access to its complete QIAstat-Dx bloodstream infection portfolio.

The company said the new QIAstat-Dx BCID GN Plus AMR Panel identifies 13 gram-negative bacterial pathogen targets and 18 antimicrobial resistance markers, with results available in about one hour. Together with the previously cleared panel for gram-positive bacteria and fungi, the two panels cover 33 pathogen targets and 28 antimicrobial resistance markers.

Disclaimer...

en | boerse | 70194261 |